Bu çalışma, tip 1 diabetik hastalarda antitiroid antikorlardan anti-tiroglobulin antikor (anti-TG ab) ve anti-peroksidaz antikor (anti-TPO ab) düzeylerini araştırmak amacıyla yapıldı. Bu amaçla, Tip 1 diabetli glisemik kontrol altındaki 20 hasta (12'si kadın, 8'i erkek) çalışma grubu olarak alındı. Bu hastalarla karşılaştırma yapmak amacıyla Tip 2 diabetli 20 hasta (14'ü kadın, 6'sı erkek) ile 20 sağlıklı birey (15'i kadın, 5 'i erkek) kontrol grubu olarak alındı. Her üç grupta da serum glukoz, T3, T4, TSH, FT3, FT4, anti-Tg ab, anti-TPO ab ölçümleri yapıldı. Kontrol ve hasta gruplarına ait bulgular istatistiksel olarak karşılaştırıldığında her üç grup arasında serum T3, T4 ve FT4'te istatistiksel açıdan önemli bir fark tespit edilemedi. Tip 1 diabet grubunun anti-Tg ab ve anti-TPO ab seviyeleri, kontrol grubuna ve tip 2 diyabet grubuna göre anlamlı derecede yüksek bulunurken(p
The aim of the present study was to investigate the levels of anti-Tg ab and anti-TPO ab in type 1 diabetes mellitus. For this purpose, 20 patients with type 1 diabetes mellitus (12 women, 8 men), 20 patients with type 2 diabetes mellitus (14 women, 6 men ) and 20 healthy volunteers (15 women, 5 men) were included. Serum glucose, T3, T4, TSH, FT3, FT4, anti-TPO ab and Anti-Tg ab levels were measured in all subjects. T3, T4 and FT4 levels were similar in all groups. Anti-TPO ab and anti-Tg ab levels were significantly higher in type 1 diabetes when compared to type 2 diabetics and healthy controls (p< 0.05). Thyroid antibody levels were higher in type 2 diabetics than healthy controls but the difference was not statistically significant. In type 1 diabetic group, serum TSH level was significantly higher and serum FT3 level was significantly lower when compared to type 2 diabetics and healthy controls (p<0.05). Frequency of anti-Tg ab and anti-TPO ab presence were 25% and 45% in type 1 diabetic group, respectively. Our results showed that thyroid autoantibody prevalence was high in type 1 diabetes, and these patients had increased risk for hypothyroidism. Thus, we suggest that thyroid functions should be frequently evaluated in type 1 diabetics with high anti-TPO ab and anti-TG ab levels.
1. Ruderman NB, Williamson JR, Drownlee M: Glucose and diabetic vascular disease. FABESJ6: 2905-2914, 1992.
2. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB, Monciotti CM, Rigon R: Clinical and subclinical organ-spesific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first degree relatives. Diabetologia 26: 431-436, 1989.
3. Jovanovic-Peterson L, Peterson CM: De novo clinical hypothyroidism in pregnancies compliated by type 1 diabetes, subclinical hypothyroidism, and proteinuria : a new syndrome. Am J Obstet Gynecol 159: 442-446, 1988.
4. Yokota I, Matsuda J, Naito E, Ito M, Shima K, Kuroda Y: Comparison of GAD and ICA512/IA-2 antibodies et and after the onset of IDDM. Diabetes Care 21: 49-52, 1998.
5. Fernandez SL, Gonzales A, Antonio JL, Antonio L, Peterson CM, Escobar F: Thyroid peroxidase autoantibodies predict poor metabolic control and need for thyroid treatment in pregnant IDDM women. Diabetes Care 20: 1524-1528, 1997.
6. Cardoso C, Ohwovoriole AE, KuKu SF: A study thyroid function and prevalence of thyroid otoantibadies and thyroid autoimmune disease in an African diabetic population. J Diabetes Complications 9:37-41, 1995.
7. Fernandez SL, Campos MM.,Gonzales JA, Escobar F: Autoimmunidead thyroidea diabetes mellitus. Diabetologia 12: 42, 1996.
8. Prina Cerai LM, Weber G, Meschi F, Mora S, Bognetti E, Siragusa V, Di Natale B: Prevalence of thyroid otoantibadies and thyroid autoimmune disease in diabetic children and adolescents. Diabetes Care 17:782-783, 1994.
9. Rattarasarn C, Diasdado MA, Ortego J, Leelawattana R, Soonthornpun S, Setasuban W, Jaruratanasirikul S, Patarakijvanich N. Thyroid autoantibodies in Thai type 1 diabetic patients: clinical significance and their relationship with glutamic acid decarboxilase antibodies. Diabetes Res Clin Pract 49: 107-11, 2000.
10. Radetti G, Paganini C, Gentili L, Bemasconi S, Betterle C, Borkenstein M,Cvijovi K, Kadranka M, Krzisnik C, Battelino T: Frequency of Hasimoto 's thyroiditis in children with type 1 diabetes mellitus. Diabetologia 32:121-124, 1995.
11. Verge CF, Hovard NJ, Rowley MJ, Mackay IR, Zimmet PZ, Egan M, Hulinska H, Hulinsky I, Silvestrini RA, Kamath S, Sharp A, Arundel T, Si link M: Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia 37; 1113-1120, 1994.
12. Martino GV, Tappaz ML, Braghi S: Autoanti-bodies to glutamic acid decarboxylase (GAD) detected by an immune-trapping enzyme activity assay: relation to insulin-dependent diabetes mellitus. J Autoimmunity 4: 915-923, 1991.
13. Ascher H, Lanner A, Kristiansson B: A new labora-tory kit for anti-gliadin IgA at diagnosis and follow-up of childhood celiac disease. J Ped. Gastro. Nutrition 10: 443-450, 1990.
14. Haslett C, Chi levers ER, Hunter JAA, Boon NA: Davidson's Principles and Practice of Medicine, 18 nd .Ed, Churchill Livingstone, 1999.
15.Jacquez O: Mediators of thyroid in children. J.Clin.Endocrinol.Metab. 29: 2595- 2599, 1998.